Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGARFiled 2 days ago

Boston Scientific (BSX) reports a director or officer change

Open the sourceReported by SEC EDGAR, sec.gov, 17 November 2026, by SEC EDGAR

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Boston Scientific’s board approved a 2027 Annual Bonus Plan on November 17, 2026, keeping the structure largely unchanged from 2026, according to a Form 8-K filed with the SEC. The plan sets an aggregate bonus pool based on participants’ target bonuses and a dynamic pool capped at 10% of total targets, with the compensation committee able to set a distribution percentage from 0% to 150% based on global sales and adjusted EPS goals. Individual performance modifiers of 0% to 150% can lift maximum payouts to 225% of target, while the board retains discretion to cut the distribution percentage based on quality objectives and quality-system performance. Executive awards remain subject to the company’s discretionary recoupment policy and its Dodd-Frank clawback policy. The filing is a routine governance disclosure rather than a management change, and investors will watch whether sales and adjusted EPS results support payouts near the top of the range.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR's report. It can get details wrong, so check the source.

Named in this story

Boston Scientific (BSX), Board of Directors, Executive Compensation and Human Resources Committee

A linked name opens that asset's sentiment page.